Skip to content.

Stem Cell Therapeutics closes C$3.1 million unit offering

Date Closed

March 15, 2013

Lead Office



3.10 Million CAD

On March 15, 2013, Stem Cell Therapeutics Corp. announced that it had closed its previously announced prospectus offering of 12,315,000 units ("Units") at a price of C$0.25 per Unit for the aggregate gross proceeds of C$3.1 million.

Each Unit is comprised of one common share and one common share purchase warrant (the "Warrant"). Each Warrant entitles the holder to purchase an additional common share for C$0.40 for a period of 60 months following the closing of the offering. Euro Pacific Canada Inc. acted as the agent and Bloom Burton & Co. as a selling firm for the offering.

The purpose of the offering is to provide the resources necessary to conclude the acquisition of Trillium Therapeutics Inc. by SCT, announced February 4th, 2013, and to trigger a condition precedent to permit the exercise of the option by SCT to acquire the license to the Tigecycline intellectual property from the University Health Network/MaRS Innovation, Toronto, announced November 7th, 2012. The assets expected to be acquired and license will conclude the initial step of SCT's published corporate objectives for advancing the Corporation's interests.

Stem Cell Therapeutics Corp., headquartered in Toronto, is a life sciences company developing stem cell-related technologies.

McCarthy Tétrault LLP represented Stem Cell Therapeutics, with a team led by Rick Pawluk.